Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
Titel:
Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
Auteur:
Wang, Michael Jurczak, Wojciech Trneny, Marek Belada, David Wrobel, Tomasz Ghosh, Nilanjan Keating, Mary-Margaret van Meerten, Tom Alvarez, Ruben Fernandez von Keudell, Gottfried Thieblemont, Catherine Peyrade, Frederic Andre, Marc Hoffmann, Marc Szafer-Glusman, Edith Lin, Jennifer Dean, James P Neuenburg, Jutta K Tam, Constantine S